Singapore markets close in 2 hours 6 minutes

  • Straits Times Index

    2,994.02
    -23.13 (-0.77%)
     

  • Nikkei

    28,631.45
    -125.41 (-0.44%)
     

  • Hang Seng

    29,524.09
    -403.67 (-1.35%)
     

  • FTSE 100

    6,715.42
    -24.97 (-0.37%)
     

  • BTC-USD

    31,617.54
    +1,049.83 (+3.43%)
     

  • CMC Crypto 200

    623.35
    +13.36 (+2.19%)
     

  • S&P 500

    3,853.07
    +1.22 (+0.03%)
     

  • Dow

    31,176.01
    -12.39 (-0.04%)
     

  • Nasdaq

    13,530.92
    0.00 (0.00%)
     

  • Gold

    1,859.90
    -6.00 (-0.32%)
     

  • Crude Oil

    52.47
    -0.66 (-1.24%)
     

  • 10-Yr Bond

    1.1090
    0.0000 (0.00%)
     

  • FTSE Bursa Malaysia

    1,603.94
    +9.14 (+0.57%)
     

  • Jakarta Composite Index

    6,284.92
    -128.97 (-2.01%)
     

  • PSE Index

    7,045.83
    -94.46 (-1.32%)
     

Facebook Had 'Incredible' Quarter Despite Boycott: Analyst

Oct.29 -- Debra Aho Williamson, principal analyst at E-Marketer Inc., discusses earnings reports by both Facebook Inc. and Twitter Inc. on "Bloomberg Technology."

Latest stories

  • Shark may have seized Australian snorkeler, police say

    A man who went missing while snorkelling off the Australian coast may have been taken by a shark, authorities said on Friday, after a search operation found pieces of diving equipment. The man went missing late on Thursday while snorkelling near Port MacDonnell, on the country's south coast, sparking an air and sea search, police said. "We haven't recovered any remains but there are a few remaining areas of interest that we want to explore, but the search will be scaled down," the Australian Broadcasting Corp quoted South Australia Police Limestone Coast operations manager Campbell Hill as saying.

  • Original Starbucks Boarded up Following Seattle Protest Vandalism

    The original Starbucks coffee shop in Seattle’s Pike Place Market was boarded up after it was vandalized during January 20 protests, footage shared to Twitter shows.Police said in a January 21 statement three people had been arrested for “crimes including property damage, burglary, and felony assault” in Seattle’s Downtown area. It was not clear whether the arrests were directly connected to the vandalism of the Starbucks.This footage, shot by Brendan Gutenschwager, shows the historic Starbucks shopfront secured with plywood. A note stapled to the boarded up door states the store is “temporarily closed”.“Please accept our apologies for any inconvenience,” the note reads. “We are working to re-open our store as quickly as possible.” Credit: Brendan Gutenschwager via Storyful

  • Mongolian prime minister resigns after COVID-19 protests

    Mongolia's parliament has approved the resignation of Prime Minister Khurelsukh Ukhnaa after protests in the capital Ulaanbaatar over the government's handling of the COVID-19 pandemic, the state news agency, Montsame, said. Khurelsukh said in a resignation statement submitted on Thursday that he should "assume the responsibility upon himself and accept the demand of the public." He will be replaced by Oyun-Erdene Luvsannamsrai, the chief cabinet secretary, Montsame said.

  • Crescent NV Enters Into a Financing Agreement With LDA Capital Limited

    Crescent (EURONEXT: OPTI; OTC: OPNVY) announces it has entered into a financing agreement with LDA Capital Limited,.

  • Outplacement Services Market Research Report - Global Forecast to 2024 - Cumulative Impact for COVID-19 Recovery - SpendEdge

    The Outplacement Services market will register an incremental spend of about USD 0.49 billion, growing at a CAGR of 5.06% from 2020-2024

  • 'Bating Filipino': MPs in Philippines pass bill to create new Covid-safe greeting

    'Bating Filipino': MPs in Philippines pass bill to create new Covid-safe greetingContactless greeting will help fight pandemic, say MPs of worst-hit country in south-east Asia, though some people would prefer more action on a vaccine * Coronavirus – latest updates * See all our coronavirus coverage

  • ONO Receives a Manufacturing and Marketing Approval of Adlumiz® (Anamorelin), a Ghrelin Receptor Agonist for the Treatment of Cancer Cachexia in Japan

    ONO Receives a Manufacturing and Marketing Approval of Adlumiz® (Anamorelin), a Ghrelin Receptor Agonist for the Treatment of Cancer Cachexia in Japan Not intended for US media Lugano, Switzerland, and Osaka, Japan, January 22, 2021 - Helsinn Group (Lugano, Switzerland; CEO: Riccardo Braglia, “Helsinn”) and Ono Pharmaceutical Co., Ltd. (Osaka, Japan; President and Representative Director: Gyo Sagara; “ONO”) announced today that ONO received the manufacturing and marketing approval of Adlumiz® (generic name: anamorelin hydrochloride) Tablet 50mg (“Adlumiz”), a ghrelin receptor agonist, for the treatment of cancer cachexia in malignant tumors of non-small cell lung cancer, gastric cancer, pancreatic cancer or colorectal cancer in Japan. This approval is mainly based on the results from the following two clinical studies conducted in Japan in patients with cancer cachexia: Phase II multi-center, randomized, double-blind, placebo-controlled, parallel group study in cancer cachexia patients with non-small cell lung cancer (ONO-7643-04)Phase III multi-center, open-label, uncontrolled study in cancer cachexia patients with gastric, pancreatic or colorectal cancer (ONO-7643-05) Cancer cachexia is a complex metabolic disorder syndrome, characterized by decreased body weight (especially decreased muscle mass) and anorexia associated with cancer. It has been well documented that cancer cachexia causes a significant impact on patients’ quality of life and prognosis. To date, an effective treatment method for cancer cachexia has not yet been established. Anamorelin is a selective, novel, orally active ghrelin receptor agonist. Ghrelin is an endogenous peptide primarily secreted by the stomach. Upon binding to its receptor, ghrelin stimulates multiple pathways in the positive regulation of body weight, muscle mass, appetite and metabolism. Anamorelin has shown effects in increasing body weight and muscle mass, as well as appetite in patients with cancer cachexia. Riccardo Braglia, Helsinn Group Vice Chairman and CEO commented: “We are delighted that Ono’s application has been successful for the treatment of cancer cachexia in Japan. This is an important milestone towards the improvement of the quality of life for all cancer cachexia patients, a condition that is still largely untreatable.” Kiyoaki Idemitsu, Corporate Executive Officer and Executive Director, Clinical Development of ONO commented: “We are extremely pleased that Adlumiz has been approved for the indication of cancer cachexia in Japan. We believe that today’s approval can provide a promising new treatment option for the patients suffering from cancer cachexia for which there previously were no other approved treatment methods”. Overview of Adlumiz® Tablet 50 mg Product NameAdlumiz® Tablet 50mgGeneric name (JAN)Anamorelin hydrochlorideIndicationCancer cachexia in the following malignant tumors:Non-small cell lung cancer, gastric cancer, pancreatic cancer and colorectal cancerDosage and administrationUsually, for adults, administer 100 mg of anamorelin hydrochloride at fasting state orally once a dayManufacturer/distributorOno Pharmaceutical Co., Ltd.Approval dateJanuary 22, 2021Conditions for approval Risk Management Plan should be designed and appropriately implemented.A post-marketing use-results survey covering all cases should be performed until data on a certain number of patients have been accumulated after the launch of the product in order to collect safety and efficacy data as early as possible and take measures necessary for the proper use of the product. About the ONO and Helsinn CollaborationIn accordance with a license agreement in force with Helsinn Healthcare SA (a company of the Helsinn Group), ONO has exclusive rights to develop and commercialize Anamorelin in Japan, South Korea and Taiwan. Helsinn retains full rights in the rest of the world. About Ono Pharmaceutical Co., Ltd.Ono Pharmaceutical Co., Ltd., headquartered in Osaka, is an R&D-oriented pharmaceutical company committed to creating innovative medicines in specific areas. ONO focuses on the oncology, immunology, neurology and specialty research with high medical needs as priority areas toward discovery and development of innovative new drugs. For further information, please visit the company’s website at www.ono.co.jp/eng. About the Helsinn GroupHelsinn is a privately-owned Swiss Pharma Company which, since 1976, has been improving the lives of patients, guided by core family values of respect, integrity and quality. The Group has an extensive portfolio of marketed innovative cancer and rare disease therapies, a robust drug development pipeline and ambitions to further accelerate its growth through in-licensing and acquisition to address unmet medical needs. Helsinn operates a unique integrated licensing business model, achieving success with over 80 long-standing partners in 190 countries, who share our values. The Group’s pharmaceutical business (Helsinn Healthcare) is headquartered in Lugano, Switzerland with operating subsidiaries in the U.S. (Helsinn Therapeutics US) and China (Helsinn Pharmaceuticals China) which market the Group’s products directly in these countries. The Group has additional operating subsidiaries in Switzerland (Helsinn Advanced Synthesis, an active pharmaceutical ingredient manufacturer) and Ireland (Helsinn Birex Pharmaceuticals, a drug product manufacturer). Helsinn Investment Fund was created to enhance the future of healthcare by providing funding and strategic support to innovative companies.Helsinn Group plays an active and central role in promoting social transformation in favor of people and the environment. Corporate social responsibility is at the heart of everything we do which is reinforced in the company's strategic plan by a commitment to sustainable growth.To learn more about Helsinn Group please visit www.helsinn.com The press release has been prepared in compliance with the Japanese regulations. Contacts: Helsinn Group Media ContactPaola BonviciniGroup Head of CommunicationLugano, SwitzerlandTel: +41 (0) 91 985 21 21Info-hhc@helsinn.com For more information, please visit www.helsinn.com and follow us on Twitter, LinkedIn and Vimeo. Ono Pharmaceutical Co., Ltd.Corporate Communicationspublic_relations@ono.co.jp

  • Saudi Arabia Redefines Role as World’s Defender of Muslims

    Crown Prince Mohammed bin Salman is promoting more secular national interests at a critical juncture for the kingdom.

  • 'In Paris, we are terrified of vulgarity': lessons in French style from Call My Agent!

    'In Paris, we are terrified of vulgarity': lessons in French style from Call My Agent!The costume designer from the hit French show on how the clothes make the characters – and how you can channel their effortless chic

  • One year after lockdown, Wuhan clubbers hit the dancefloor

    Glow-in-the-dark rabbit ears, pulsating beats, and a flexible attitude to masks: nightlife in China's Wuhan is back with a vengeance almost a year after a lockdown brought life to a standstill in the city of 11 million.

  • Friday briefing: Fauci enjoys giving dose of facts

    Friday briefing: Fauci enjoys giving dose of facts£500 payment on testing positive proposed in England … Nissan says Brexit gives advantage to UK factory … Judi Dench on life and lockdown

  • Intel (INTC) Q4 2020 Earnings Call Transcript

    INTC earnings call for the period ending December 31, 2020.

  • The play putting women’s toilets at centre stage

    Travis Alabanza’s 'Overflow’ focuses on a key battleground in the trans rights debate, celebrating it as a place of solidarity. It’s a joy, says Micha Frazer-Carroll

  • Chris Packham joins fight to end UK’s 'embarrassing' plastic waste exports

    Chris Packham joins fight to end UK’s 'embarrassing' plastic waste exportsTV presenter says government is reneging on Brexit green pledges by breaking with EU ban

  • BGHL (GBP): NAV(s)

    BOUSSARD & GAVAUDAN HOLDING LIMITED Ordinary Shares The Directors of Boussard & Gavaudan Holding Limited would like to announce the following information for the Company. Close of business 21 Jan 2021. Estimated NAV Euro SharesSterling SharesEstimated NAV€ 26.3747£ 23.0886Estimated MTD return 1.69 % 1.41 %Estimated YTD return 1.69 % 1.41 %Estimated ITD return 163.75 % 130.89 % NAV and returns are calculated net of management and performance fees Market information Euro SharesAmsterdam (AEX)London (LSE)Market Close€ 21.40N/APremium/discount to estimated NAV -18.86 %N/A Sterling SharesAmsterdam (AEX)London (LSE)Market CloseN/AGBX 1,800.00Premium/discount to estimated NAVN/A -22.04 % Transactions in own securities purchased into treasury Ordinary Shares Euro SharesSterling SharesNumber of sharesN/AN/AAverage PriceN/AN/ARange of PriceN/AN/A Liquidity Enhancement AgreementEuro SharesSterling SharesNumber of sharesN/AN/AAverage PriceN/AN/A BGHL Capital BGHL Ordinary SharesEuro SharesSterling SharesShares Outstanding 13,275,769 294,494Held in treasury 217,500N/AShares Issued 13,493,269 294,494 Estimated BG Fund NAV Class B Euro Shares (estimated)€ 221.9329 The Class B Euro Shares of BG Fund are not subject to investment manager fees, as the Investment Manager receives management fees and performance fees in respect of its role as Investment Manager of BGHL. For further information please contact: Boussard & Gavaudan Investment Management, LLP. Emmanuel Gavaudan +44 (0) 20 3751 5389 Email : info@bgam-uk.com The Company is established as a closed-ended investment company domiciled in Guernsey. The Company has received the necessary approval of the Guernsey Financial Services Commission and the States of Guernsey Policy Council. The Company is registered with the Dutch Authority for the Financial Markets as a collective investment scheme pursuant to article 2:73 in conjunction with 2:66 of the Dutch Financial Supervision Act (Wet op het financieel toezicht). The shares of the Company (the "Shares") are listed on Euronext Amsterdam. The Shares are also listed on the Official List of the UK Listing Authority and admitted to trading on the London Stock Exchange plc's main market for listed securities. This is not an offer to sell or a solicitation of any offer to buy any securities in the United States or in any other jurisdiction. This announcement is not intended to and does not constitute, or form part of, any offer or invitation to purchase any securities or the solicitation of any vote or approval in any jurisdiction, nor shall there be any sale, issuance or transfer of the securities referred to in this announcement in any jurisdiction in contravention of applicable law. Neither the Company nor BG Fund ICAV has been, and neither will be, registered under the US Investment Company Act of 1940, as amended (the "Investment Company Act"). In addition the securities referenced in this announcement have not been and will not be registered under the US Securities Act of 1933, as amended (the "Securities Act"). Consequently any such securities may not be offered, sold or otherwise transferred within the United States or to, or for the account or benefit of, US persons except in accordance with the Securities Act or an exemption therefrom and under circumstances which will not require the issuer of such securities to register under the Investment Company Act. No public offering of any securities will be made in the United States. You should always bear in mind that: all investment is subject to risk; results in the past are no guarantee of future results; the investment performance of BGHL may go down as well as up. You may not get back all of your original investment; and if you are in any doubt about the contents of this communication or if you consider making an investment decision, you are advised to seek expert financial advice. This communication is for information purposes only and the information contained in this communication should not be relied upon as a substitute for financial or other professional advice. Attachment Daily NAV - BgHL 21.01.2021

  • BGHL (EUR): NAV(s)

    BOUSSARD & GAVAUDAN HOLDING LIMITED Ordinary Shares The Directors of Boussard & Gavaudan Holding Limited would like to announce the following information for the Company. Close of business 21 Jan 2021. Estimated NAV Euro SharesSterling SharesEstimated NAV€ 26.3747£ 23.0886Estimated MTD return 1.69 % 1.41 %Estimated YTD return 1.69 % 1.41 %Estimated ITD return 163.75 % 130.89 % NAV and returns are calculated net of management and performance fees Market information Euro SharesAmsterdam (AEX)London (LSE)Market Close€ 21.40N/APremium/discount to estimated NAV -18.86 %N/A Sterling SharesAmsterdam (AEX)London (LSE)Market CloseN/AGBX 1,800.00Premium/discount to estimated NAVN/A -22.04 % Transactions in own securities purchased into treasury Ordinary Shares Euro SharesSterling SharesNumber of sharesN/AN/AAverage PriceN/AN/ARange of PriceN/AN/A Liquidity Enhancement AgreementEuro SharesSterling SharesNumber of sharesN/AN/AAverage PriceN/AN/A BGHL Capital BGHL Ordinary SharesEuro SharesSterling SharesShares Outstanding 13,275,769 294,494Held in treasury 217,500N/AShares Issued 13,493,269 294,494 Estimated BG Fund NAV Class B Euro Shares (estimated)€ 221.9329 The Class B Euro Shares of BG Fund are not subject to investment manager fees, as the Investment Manager receives management fees and performance fees in respect of its role as Investment Manager of BGHL. For further information please contact: Boussard & Gavaudan Investment Management, LLP. Emmanuel Gavaudan +44 (0) 20 3751 5389 Email : info@bgam-uk.com The Company is established as a closed-ended investment company domiciled in Guernsey. The Company has received the necessary approval of the Guernsey Financial Services Commission and the States of Guernsey Policy Council. The Company is registered with the Dutch Authority for the Financial Markets as a collective investment scheme pursuant to article 2:73 in conjunction with 2:66 of the Dutch Financial Supervision Act (Wet op het financieel toezicht). The shares of the Company (the "Shares") are listed on Euronext Amsterdam. The Shares are also listed on the Official List of the UK Listing Authority and admitted to trading on the London Stock Exchange plc's main market for listed securities. This is not an offer to sell or a solicitation of any offer to buy any securities in the United States or in any other jurisdiction. This announcement is not intended to and does not constitute, or form part of, any offer or invitation to purchase any securities or the solicitation of any vote or approval in any jurisdiction, nor shall there be any sale, issuance or transfer of the securities referred to in this announcement in any jurisdiction in contravention of applicable law. Neither the Company nor BG Fund ICAV has been, and neither will be, registered under the US Investment Company Act of 1940, as amended (the "Investment Company Act"). In addition the securities referenced in this announcement have not been and will not be registered under the US Securities Act of 1933, as amended (the "Securities Act"). Consequently any such securities may not be offered, sold or otherwise transferred within the United States or to, or for the account or benefit of, US persons except in accordance with the Securities Act or an exemption therefrom and under circumstances which will not require the issuer of such securities to register under the Investment Company Act. No public offering of any securities will be made in the United States. You should always bear in mind that: all investment is subject to risk; results in the past are no guarantee of future results; the investment performance of BGHL may go down as well as up. You may not get back all of your original investment; and if you are in any doubt about the contents of this communication or if you consider making an investment decision, you are advised to seek expert financial advice. This communication is for information purposes only and the information contained in this communication should not be relied upon as a substitute for financial or other professional advice. Attachment Daily NAV - BgHL 21.01.2021

  • Nicox Analyst Coverage Initiated by Edison Investment Research

    Press ReleaseNicox Analyst Coverage Initiated by Edison Investment Research January 22, 2021 – release at 7:30 am CET Sophia Antipolis, France Nicox SA (Euronext Paris: FR0013018124, COX), an international ophthalmology company, today announced that Edison, an investment research and advisory company with a world-renowned equity research platform and deep international healthcare expertise, has initiated equity research coverage of Nicox. The financial report by Edison, released on January 21, 2021, is available on the Edison website https://www.edisongroup.com/publication/focus-on-sight/28664. Nicox is also covered by Bryan, Garnier & Co. and Kepler Cheuvreux in France, and H.C Wainwright & Co., Oppenheimer & Co. Inc. and Cantor Fitzgerald in the U.S. Michele Garufi, Chairman and CEO of Nicox, will present at the Edison Open House Global Healthcare Conference 2021 being held virtually on January 26-28, 2021. The video webcast of Nicox's presentation will be available on-demand by clicking here and accessible on Nicox's website (www.nicox.com) in the “Presentations & Events” section. About NicoxNicox S.A. is an international ophthalmology company developing innovative solutions to help maintain vision and improve ocular health. Nicox’s lead program in clinical development is NCX 470, a novel nitric oxide-donating prostaglandin analog, for lowering intraocular pressure in patients with glaucoma. The company is also developing NCX 4251, a proprietary formulation of fluticasone, for acute exacerbations of blepharitis. Nicox generates revenue from VYZULTA® in glaucoma, licensed exclusively worldwide to Bausch + Lomb, and ZERVIATE™ in allergic conjunctivitis, licensed in multiple geographies, including to Eyevance Pharmaceuticals, LLC, in the U.S. and Ocumension Therapeutics in the Chinese and in the majority of South East Asian markets. Nicox is headquartered in Sophia Antipolis, France, is listed on Euronext Paris (Compartment B: Mid Caps; Ticker symbol: COX) and is part of the CAC Healthcare, CAC Pharma & Bio and Next 150 indexes. For more information on Nicox, its products or pipeline, please visit: www.nicox.com.Analyst coverage Bryan, Garnier & Co Victor Floc’h Paris, FranceCantor Fitzgerald Louise Chen New York, U.S.Edison Pooya Hemami London, U.K.H.C. Wainwright & Co Yi Chen New York, U.S.Kepler Cheuvreux Damien Choplain Paris, FranceOppenheimer & Co Hartaj Singh New York, U.S. The views expressed by analysts in their coverage of Nicox are those of the author and do not reflect the views of Nicox. Additionally, the information contained in their reports may not be correct or current. Nicox disavows any obligation to correct or to update the information contained in analyst reports. ContactsNicoxGavin SpencerExecutive Vice President, Chief Business Officer& Head of Corporate Development T +33 (0)4 97 24 53 00communications@nicox.com Investors & MediaUnited States & Europe LifeSci Advisors, LLC Mary-Ann Chang T +44 7483 284 853mchang@lifesciadvisors.comMediaFranceLifeSci Advisors, LLCSophie BaumontM +33 (0)6 27 74 74 49 sophie@lifesciadvisors.comForward-Looking StatementsThe information contained in this document may be modified without prior notice. This information includes forward-looking statements. Such forward-looking statements are not guarantees of future performance. These statements are based on current expectations or beliefs of the management of Nicox S.A. and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Nicox S.A. and its affiliates, directors, officers, employees, advisers or agents, do not undertake, nor do they have any obligation, to provide updates or to revise any forward-looking statements. Risks factors which are likely to have a material effect on Nicox’s business are presented in the 3rd chapter of the ‘Document d’enregistrement universel, rapport financier annuel et rapport de gestion 2019’ filed with the French Autorité des Marchés Financiers (AMF) on March 6, 2020 which is available on Nicox’s website (www.nicox.com) and in the 4th chapter of the half yearly financial report as of June 30, 2020, which is also available on Nicox’s website..Nicox S.A.Drakkar 2 Bât D, 2405 route des Dolines CS 10313, Sophia Antipolis 06560 Valbonne, France T +33 (0)4 97 24 53 00 F +33 (0)4 97 24 53 99 Attachment EN_Edison Nicox Initiation PR_20210122_F1

  • Nidec Announces the Status of Share Repurchases and the Conclusion of the Share Repurchase Plan

    (Repurchases of Shares Pursuant to Article 459, Paragraph 1, Item 1 of the Company Law of Japan)KYOTO, Japan, Jan. 22, 2021 (GLOBE NEWSWIRE) -- Nidec Corporation (TSE: 6594; OTC US: NJDCY) (the ”Company”) today announces the status of the Company’s share repurchases under its repurchase plan in accordance with the Articles of Incorporation pursuant to Article 459, Paragraph 1, Item 1 of the Company Law of Japan. The Company’s share repurchase plan authorized by the Board of Directors on January 23, 2020, and February 8, 2020 has been concluded as of January 22, 2021. Neither the number nor yen amount of the shares repurchased reached the predetermined upper limits due mainly to: the Company's stock price remaining within the expected range, anduptrend of the Company's stock price in the latter half of the current period of share repurchase. Details of Share Repurchase 1. Period of share repurchase: From January 1, 2021 through January 22, 20212. Class of shares: Common stock3. Number of shares repurchased: 0 shares4. Total repurchase amount: 0 yen Note: The above repurchase information has been prepared on the basis of trade date. Reference A) Details of the share repurchase plan authorized by the Board of Directors on January 23, 2020 and February 8, 20201. Class of shares: Common stock2. Total number of shares that may be repurchased: Up to 8,000,000 shares(1.36% of total number of shares issued, excluding treasury stock)3. Total repurchasable amount: 50 billion yen4. Period of repurchase: From January 24, 2020 through January 22, 2021 B) Total number and yen amount of shares repurchased from January 24, 2020 through January 22, 2021, pursuant to the authorization of the Board of Directors described above: 1. Total number of shares repurchased: 2,850,200 shares2. Total repurchase amount: 18,527,768,000 yen Contact: Masahiro Nagayasu General Manager Investor Relations +81-75-935-6140 ir@nidec.com

  • COVID-19: 14 Vietnamese fined for large gathering at flat during Phase 1

    14 Vietnamese nationals were fined between $2,500 and $3,500 for COVID-19 breaches, including having an illegal social gathering.

  • China's INE completes first overseas delivery of low-sulphur fuel oil contract

    The Shanghai International Energy Exchange (INE) said on Friday it had completed first delivery of its clean marine fuel futures contract outside China, a trial it started recently in Singapore to boost liquidity of the contract. Trafigura Pte Ltd and Freepoint Commodities Singapore Pte Ltd earlier this week took a combined 2,500 tonnes of the very low-sulphur fuel oil from a PetroChina-owned storage picked by INE as its first overseas delivery point. China-Base Resource Singapore is expected to take another 1,000 tonnes of delivery from the same storage between Jan. 22-24.